Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex Seeks To Maintain 156 Days Of Exclusivity For Generic Plavix

This article was originally published in The Pink Sheet Daily

Executive Summary

Apotex petitions FDA to stay action on other clopidogrel ANDAs, as Dr. Reddy’s gets into position for a generic launch.

You may also be interested in...



Generic Plavix Is Expected to Launch in Germany In Mid-August

The two companies with rights to market a generic version of Plavix (clopidogrel) in Germany are mum about their launch date. But Sanofi-Aventis, which markets Plavix with Bristol-Myers Squibb, does not expect to see generic products on the German market before mid-August

Generic Plavix Is Expected to Launch in Germany In Mid-August

The two companies with rights to market a generic version of Plavix (clopidogrel) in Germany are mum about their launch date. But Sanofi-Aventis, which markets Plavix with Bristol-Myers Squibb, does not expect to see generic products on the German market before mid-August

Plavix Patent Upheld By Court, Blocking Generic Clopidogrel

Apotex says it will immediately appeal the decision in favor of Sanofi-Aventis/Bristol-Myers Squibb.

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel